Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

JAMA 2010 Sep;304(9):967-75

Abramson Cancer Center and Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA.

Context: Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer.

Objective: To estimate risk and mortality reduction stratified by mutation and prior cancer status.

Design, Setting, And Participants: Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008. The study was conducted at 22 clinical and research genetics centers in Europe and North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. The women were followed up until the end of 2009.

Main Outcomes Measures: Breast and ovarian cancer risk, cancer-specific mortality, and overall mortality.

Results: No breast cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372 diagnosed with breast cancer who did not have risk-reducing mastectomy. Compared with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent salpingo-oophorectomy had a lower risk of ovarian cancer, including those with prior breast cancer (6% vs 1%, respectively; hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.04-0.59) and those without prior breast cancer (6% vs 2%; HR, 0.28 [95% CI, 0.12-0.69]), and a lower risk of first diagnosis of breast cancer in BRCA1 mutation carriers (20% vs 14%; HR, 0.63 [95% CI, 0.41-0.96]) and BRCA2 mutation carriers (23% vs 7%; HR, 0.36 [95% CI, 0.16-0.82]). Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs 3%; HR, 0.40 [95% CI, 0.26-0.61]), breast cancer-specific mortality (6% vs 2%; HR, 0.44 [95% CI, 0.26-0.76]), and ovarian cancer-specific mortality (3% vs 0.4%; HR, 0.21 [95% CI, 0.06-0.80]).

Conclusions: Among a cohort of women with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with a lower risk of ovarian cancer, first diagnosis of breast cancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality.

Download full-text PDF

Source
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.20
Publisher Site
http://dx.doi.org/10.1001/jama.2010.1237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948529PMC
September 2010
32 Reads

Publication Analysis

Top Keywords

breast cancer
24
cancer-specific mortality
20
brca1 brca2
16
risk-reducing mastectomy
16
lower risk
16
cancer
12
brca2 mutations
12
ovarian cancer
12
mutation carriers
12
associated lower
12
compared women
12
risk-reducing salpingo-oophorectomy
12
breast
11
mortality
9
mastectomy compared
8
mastectomy salpingo-oophorectomy
8
prior breast
8
breast cancer-specific
8
diagnosis breast
8
ovarian cancer-specific
8

Similar Publications